Clinical Trials Logo

Filter by:
NCT ID: NCT03703310 Completed - Clinical trials for Basal Cell Nevus Syndrome

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Start date: February 19, 2019
Phase: Phase 3
Study type: Interventional

This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational product for 12 months. The primary endpoint is a comparison between the two treatment arms of the number of new BCCs that develop over the 12 month period.

NCT ID: NCT03703128 Completed - Suicide Clinical Trials

Suicide in People Aged 45-60: A Case-control Psychological Autopsy Study

Start date: September 28, 2018
Phase:
Study type: Observational

The purpose of this study is to learn about the possible causes of the negative trend in suicide rates in both males and females aged 45-60 in Flanders, Belgium. This will be carried out using a psychological autopsy study.

NCT ID: NCT03698539 Completed - Down Syndrome Clinical Trials

How Stuttering and Gestures Influence the Intelligibility of Individuals With Down Syndrome

Start date: December 5, 2018
Phase:
Study type: Observational

This study wants to determine the relationship between spontaneous hand gestures, stuttering and intelligibility in individuals with Down syndrome. One third of these individuals has fluency problems, such as stuttering. Gesture use appears to be a strength in individuals with Down syndrome. While they are able to compensate for their language problems, it is not clear if they also use gestures to compensate for their speech problems. Therefore, this study will observe the impact of their gesture use on the stuttering frequency/severity and on the intelligibility of children with Down syndrome. This study has three research questions. The first question is: Is there a difference in gesture use between individuals with Down syndrome who stutter and individuals with Down syndrome who do not stutter? The hypothesis is that the children who stutter will make more gestures to compensate for the fluency problems. The kind of spontaneous hand gestures will also be considered. These results will be compared to those of typical developing individuals. The second research question is: Are stuttering events that are accompanied by a gesture more intelligible than stuttering moments that are not accompanied by a gesture? Research showed that the use of signs has an positive impact on the speech intelligibility of individuals with Down syndrome. Here it is investigated if this is also true for spontaneous hand gestures. In case of better speech intelligibility it is investigated if the gain in intelligibility is caused by how recognizable the gesture is or by the effect of the gestures on speech itself. The effect of different types on the speech intelligibility of the stuttering events will also be investigated. Typically developing individuals who stutter will function as control group. The third research question is: 'Does gestural priming have an influence on the fluency of children with Down syndrome? Gestural priming is a secondary speech signal that gives feedback to the first speech signal by simultaneously mimicking the first speech signal. In this research a hand puppet will imitate the mouth movements of the participants. Next to that, the speech will be simultaneously be accompanied by beat gestures, meaningless up and downward movements. The hypothesis is that due to mirror neurons, the participants will become more fluent. Mirror neurons are neurons in the brain that can produce a neural basis for fluency by the perception of the second speech signal.

NCT ID: NCT03697213 Completed - Palliative Care Clinical Trials

The Surprise Study

Start date: March 25, 2019
Phase:
Study type: Observational

This study investigates the use of the Surprise Question [SQ] (would you be surprised if this patient were to die in the next 12 months?) in routine practice. In particular, the study will investigate the consistency of the responses to the SQ and the relationship with the subsequent course of action decided upon.

NCT ID: NCT03696459 Completed - Healthy Clinical Trials

A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants

Start date: October 2, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of JNJ-53718678 on QT interval corrected for heart rate (QTc) changes using exposure response analysis in healthy adult participants (Part 2).

NCT ID: NCT03696095 Completed - Postoperative Pain Clinical Trials

Local Anesthetic Automated Intermittent Administration vs. Continuous Infusion Via Femoral Nerve Block.

Start date: April 16, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the impact of local anesthetic administration regiment through peri-neural femoral nerve catheter on pain and motor block frequency, after total knee arthroplasty.

NCT ID: NCT03694522 Completed - Gastric Cancer Clinical Trials

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

FIGHT
Start date: September 14, 2018
Phase: Phase 2
Study type: Interventional

The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.

NCT ID: NCT03693170 Completed - Clinical trials for BRAF V600E-mutant Metastatic Colorectal Cancer

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

ANCHOR-CRC
Start date: January 17, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.

NCT ID: NCT03691337 Completed - THA Clinical Trials

Fascia Iliaca Blocks for Total Hip Arthroplasty

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

The development of minimal-incision techniques for total hip arthroplasty (THA) with preservation of soft tissue is generally associated with reduction of postoperative pain and increased patient comfort. Although this technique requires a smaller incision than other approaches used for hip surgery, adequate postoperative pain management remains crucial for enhanced recovery and early rehabilitation. The fascia iliaca block (FIB) is commonly used to enhance analgesia after hip replacement surgery, however the effect of FIB volume on analgesia quality and sensory-motor blockade have not been adequately studied. In this study, total postsurgical opioid consumption (morphine equivalents IV in hospital and oral at home) through the first postoperative week will be compared and extent and duration of sensory motor block through the 2-day inpatient stay will be evaluated.

NCT ID: NCT03690843 Completed - Clinical trials for Developmental Coordination Disorder

Development of Children With DCD Before the Age of Six

Start date: October 8, 2018
Phase:
Study type: Observational

The aim of this study is to map the early development of children with DCD and compare it to typically developing (TD) children. At first we will investigate to what extent motor delay, reduced force, higher BMI, behavioral, ADL and participation problems occur in toddlerhood in DCD children and how this relates to TD children. We will also look into the evolution of these parameters in time (stability of development). Secondly we will explore if the diagnosis of DCD can be predicted using a standardized test before the age of five.